6 курс / Кардиология / Джон_Кэмм_Болезни_сердца_и_сосудов_2011
.pdf120.Van Wagoner D.R. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target //
J. Cardiovasc. Pharmacol. - 2008. - 2008. - Vol. 52. - P. 306-313.
121.Dudley S.C., Jr., Hoch N.E., McCann L.A. et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases // Circulation. -
2005. - Vol. 112. - P. 1266-1273.
122.Liu T., Li G., Li L. et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis // J. Am. Coll. Cardiol. - 2007. - Vol. 49. -
P. 1642-1648.
123.Aviles R.J., Martin D.O., Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation // Circulation. - 2003. - Vol. 108. -
P. 3006-3010.
124.Spach M.S., Heidlage J.F., Dolber P.C. et al. Mechanism of origin of conduction disturbances in aging human atrial bundles: experimental and model study // Heart Rhythm. - 2007. - Vol. 4. - P. 175-185.
125.Lai L.P., Tsai C.C., Su M.J. et al. Atrial fibrillation is associated with accumulation of aging-related common type mitochondrial DNA deletion mutation in human atrial tissue // Chest. - 2003. - Vol. 123. -
P. 539-544.
126.Madej-Pilarczyk A., Kmiec T., Fidzianska A. et al. Progeria caused by a rare LMNA mutation p.S143F associated with mild myopathy and atrial fibrillation // Eur. J. Paediatr. Neurol. - 2008. - Vol. 12. -
P. 427-430.
127.Schotten U., Duytschaever M., Ausma J. et al. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand // Circulation. - 2003. - Vol. 107. - P. 1433-1439.
128.Sun H., Gaspo R., Leblanc N., Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia // Circulation. - 1998. - Vol. 98. - P. 719-727.
129.Gaborit N., Steenman M., Lamirault G. et al. Human atrial ion channel and transporter subunit geneexpression remodeling associated with valvular heart disease and atrial fibrillation // Circulation. -
2005. - Vol. 112. - P. 471-481.
130.Dobrev D., Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics // J. Cardiovasc. Pharma-col. - 2008. - Vol. 52. - P. 293-299.
131.Cosio F.G., Aliot E., Botto G.L. et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode // Euro PACE. - 2008. - Vol. 10. - P. 21-27.
132.Li D., Melnyk P., Feng J. et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology // Circulation. - 2000. - Vol. 101. - P. 2631-2638.
133.Li D., Shinagawa K., Pang L. et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure // Circulation. - 2001. - Vol. 104. - P. 2608-2614.
134.Neuberger H.R., Schotten U., Verheule S. et al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat // Circulation. - 2005. - Vol. 111. - P. 30-37.
135.Schotten U., De Haan S., Neuberger H.R. et al. Loss of atrial contractility is the primary cause of atrial dilatation during the first days of atrial fibrillation // Am. J. Physiol. Heart Circ. Physiol. - 2004. - Vol. 287. - P. H2324-H2331.
136.Mont L., Sambola A., Brugada J. et al. Long-lasting sport practice and lone atrial fibrillation // Eur. Heart J. - 2002. - Vol. 23. - P. 477-482.
137.Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation // N. Engl. J. Med. - 1997. - Vol. 336. - P. 905-911.
138.Lehnart S.E., Ackerman M.J., Benson D.W, Jr. et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function // Circulation. - 2007. - Vol. 116. - P. 2325-2345.
139.Sinner M.F., Pfeufer A., Akyol M. et al. The non-synonymous coding IKr-channel variant KCNH2K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2. (HERG) // Eur. Heart J. - 2008. - Vol. 29. - P. 907-914.
140.Olson T.M., Alekseev A.E., Liu X.K. et al. Kv1.5. channelopathy due to KCNA5. loss-of-function mutation causes human atrial fibrilla-tion // Hum. Mol. Genet. - 2006. - Vol. 15. - P. 2185-2191.
141.Kusano K.F., Taniyama M., Nakamura K. et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 1169-1175.
142.Coronel R., Casini S., Koopmann T.T. et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study // Circulation. - 2005. - Vol. 112. - P. 2769-2777.
143.Royer A., van Veen T.A., Le Bouter S. et al. Mouse model of SCN5A-linked hereditary Lenegre’s disease: age-related conduction slowing and myocardial fibrosis // Circulation. - 2005. - Vol. 111. - P. 1738-1746.
144.Fredj S., Lindegger N., Sampson K.J. et al. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3. myocytes // Circ. Res. - 2006. - Vol. 99. - P. 1225-1232.
145.Ellinor P.T., Nam E.G., Shea M.A. et al. Cardiac sodium channel mutation in atrial fibrillation // Heart Rhythm. - 2008. - Vol. 5. - P. 99-105.
146.Olson T.M., Michels V.V., Ballew J.D. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation // JAMA. - 2005. - Vol. 293. - P. 447-454.
147.Bhuiyan Z.A., van den Berg M.P., van Tintelen J.P. et al. Expanding spectrum of human RYR2related disease: new electrocardiographic, structural, and genetic features // Circulation. - 2007. - Vol. 116. - P. 1569-1576.
148.Arad M., Moskowitz I.P., Patel V.V. et al. Transgenic mice overexpressing mutant PRKAG2. define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy // Circulation. -
2003. - Vol. 107. - P. 2850-2856.
149.Gollob M.H., Seger J.J., Gollob T.N. et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy // Circulation. - 2001. - Vol. 104. - P. 3030-3033.
150.Gollob M.H., Jones D.L., Krahn A.D. et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation // N. Engl. J. Med. - 2006. - Vol. 354. - P. 2677-2688.
151.Hodgson-Zingman D.M., Karst M.L., Zingman L.V. et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation //
N. Engl. J. Med. - 2008. - Vol. 359. - P. 158-165.
152.Gudbjartsson D.F., Arnar D.O., Helgadottir A. et al. Variants conferring risk of atrial fibrillation on chromosome 4q25 // Nature. - 2007. - Vol. 448. - P. 353-357.
153.Mommersteeg M.T., Brown N.A., Prall O.W. et al. Pitx2c and Nkx2-5. are required for the formation and identity of the pulmonary myocardium // Circ. Res. - 2007. - Vol. 101. - P. 902-909.
154.Campione M, Acosta L, Martinez S, et al. Pitx2 and cardiac development: a molecular link between left/right signaling and congenital heart disease // Cold Spring Harb Symp Quant Biol. - 2002. - Vol. 67. - P. 89-95.
155.Postma AV, van de Meerakker JB, Mathijssen IB, et al. A gain-of-function TBX5. mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation // Circ. Res. - 2008. - Vol. 102. - P. 1433-1442.
156.Verheule S., Sato T., Everett T 4th, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1 // Circ. Res. - 2004. - Vol. 94. -
P. 1458-1465.
157.Adam O., Frost G., Custodis F. et al. Role of Rac1. GTPase activation in atrial fibrillation // J. Am. Coll. Cardiol. - 2007. - Vol. 50. -
P. 359-367.
158.Muller F.U., Lewin G., Baba H.A. et al. Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice.// J. Biol. Chem. - 2005. - Vol. 280. - P. 6906-6914.
159.Sah V.P., Minamisawa S., Tam S.P. et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure // J. Clin. Invest. - 1999. - Vol. 103. - P. 16271634.
160.Glotzer T.V., Hellkamp A.S., Zimmerman J. et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and // Stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST) // Circulation. - 2003. - Vol. 107. - P. 1614-1619.
161.Meurling C.J., Waktare J.E., Holmqvist F. et al. Diurnal variations of the dominant cycle length of chronic atrial fibrillation // Am. J. Physiol. - 2001. - Vol. 280. - P. H401-406.
162.Pandozi C., Bianconi L., Villani M. et al. Local capture by atrial pacing in spontaneous chronic atrial fibrillation // Circulation. - 1997. -
Vol. 95. - P. 2416-2422.
163.Savelieva I., Camm A.J. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management // J. Interv. Card. Electrophysiol. - 2000. - Vol. 4. - P. 369-382.
164.Lin H.J., Wolf P.A., Benjamin E.J. et al. Newly diagnosed atrial fibrillation and acute // Stroke: the Framingham Study // Stroke. - 1995. - Vol. 26. - P. 1527-1530.
165.Israel C.W., Gronefeld G., Ehrlich J.R. et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care // J. Am. Coll. Cardiol. -
2004. - Vol. 43. - P. 47-52.
166.Coumel P. Neural aspects of paroxysmal atrial fibrillation. In Falk RH, Podrid PJ (eds.) Atrial Fibrillation: Mechanisms and Management, 1992. New York: Raven Press. - P. 101-117.
167.Wolf P.A., Dawber T.R., Thomas H.E. Jr. et al. Epidemiologic assessment of chronic atrial fibrillation and risk of // Stroke: the Framingham study // Neurology. - 1978. - Vol. 28. - P. 973-977.
168.Lip G.Y., Lim H.S. Atrial fibrillation and stroke prevention // Lancet Neurol. - 2007. - Vol. 6. - P. 981993.
169.Hughes M., Lip G.Y. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data // Thromb. Haemost. - 2008. - Vol. 99. - P. 295-304.
170.Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review // Neurology. - 2007. - Vol. 69. - P. 546-554.
171.Lip G.Y. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis // Thromb. Haemost 2008. Jul. - 100. - P. 11-13.
172.Kopecky S.L., Gersh B.J., McGoon M.D. et al. The natural history of lone atrial fibrillation. A population-based study over three decades // N. Engl. J. Med. - 1987. - Vol. 317. - P. 669-674.
173.AF Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066. patients from 3 clinical trials // Arch. Intern. Med. - 1998. - Vol. 158. - P. 13161320.
174.Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting // Stroke: results from the National Registry of Atrial Fibrillation // JAMA. - 2001. - Vol. 285. -
P. 2864-2870.
175.Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation // Stroke. - 2008. - Vol. 39. - P. 1901-1910.
176.Fang M.C., Go A.S., Chang Y. et al. ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 810-815.
177.Watson T., Shantsila E., Lip G.Y.H. Mechanisms of thrombogenesis in atrial fibrillation. Virchow’s triad revisited // Lancet. - 2009. - Vol. 373. - P. 155-166.
178.Takada T., Yasaka M., Nagatsuka K. et al. Blood flow in the left atrial appendage and embolic stroke in nonvalvular atrial fibrillation // Eur. J. Neurol. - 2001. - Vol. 46. - P. 148-152.
179.Ernst G., Stollberger C., Abzieher F. et al. Morphology of the left atrial appendage // Anat. Rec. - 1995. - Vol. 242. - P. 553-561.
180.Thijesen V.L., Ausma J., Liu G.S. et al. Structural changes of atrial myocardium during chronic atrial fibrillation // Cardiovasc. Pa-thol. - 2000. - Vol. 9. - P. 17-28.
181.Al-Saady N.M., Obel O.A., Camm A.J. Left atrial appendage: structure, function, and role in thromboembolism // Heart. - 1999. - Vol. 82. - P. 547-555.
182.Lip G.Y. Does atrial fibrillation confer a hypercoagulable state? // Lancet. - 1995. - Vol. 346. - P. 1313-1314.
183.McBane R.D., Hodge D.O., Wysokinski W.E. Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation // Thromb. Haemost. - 2008. - Vol. 99. - P. 951-955.
184.Tinkler .K, Cullinane M., Kaposzta Z. et al. Asymptomatic embolisation in non-valvular atrial fibrillation and its relation to anticoagulation therapy // Eur. J. Ultrasound. - 2002. - Vol. 15. - P. 21-27.
185.Singer D.E., Albers G.W., Dalen J.E. et al. - American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed) // Chest. - 2008. - Vol. 133. (Suppl.6). - P. 546S-592S.
186.Mant J., Hobbs F.D., Fletcher K. et al. - BAFTA investigators. - Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial // Lancet. - 2007. - Vol. 370. - P. 493-503.
187.Sato H., Ishikawa K., Kitabatake A. et al. - Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Japan Atrial Fibrillation Stroke Trial // Stroke. - 2006. - Vol. 37. - P. 447-451.
188.Peterson P., Boysen G., Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study // Lancet. - 1989. - Vol. i. - P. 175-179.
189.Hart R.G., Pearce L.A., Aguilar M.I. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation // Ann. Intern. Med. - 2007. - Vol. 147. - P. 590-592.
190.Stroke Prevention in Atrial Fibrillation investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J. Stroke // Cerebrovasc Dis. - 1993. - Vol. 3. - P. 181-188.
191.FFAACS (Fluindione, Fibrillation Auriculaire, Aspirine et Contraste Spontané) Investigators.
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirine et Contraste Spon-tané. - FFAACS) // Cerebrovasc. Dis. - 2001. - Vol. 12. - P. 245-252.
192.Flaker G.C., Gruber M., Connolly S.J. et al., for the SPORTIF investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials // Am. Heart J. - 2006. - Vol. 152. -
P. 967-973.
193.Lip G.Y. Don’t add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation // BMJ. - 2008. - Vol. 336. - P. 614-615.
194.Connolly S., Pogue J., Hart R. et al. - ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. - 2006. - Vol. 367. - P. 1903-1912.
195.Hart R.G., Bhatt D.L., Hacke W. et al. - CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial // Cerebrovasc. Dis. - 2008. - Vol. 25. - P. 344-347.
196.The ACTIVE Investigators, Connolly S.J., Pogue J. et al. - Effect of clopidogrel added to aspirin in patients with atrial fibrillation //
N. Engl. J. Med. - 2009. - Vol. 360. - P. 2066-2078.
197.Turpie A.G. New oral anticoagulants in atrial fibrillation // Eur. Heart J. - 2008. - Vol. 29. - P. 155-65.
198.Lip G.Y., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients withnonvalvular atrial fibrillation: a systematic review and meta-analysis // Thromb. Res. - 2006. - Vol. 118. -
P. 321-333.
199.Savelieva I., Bajpai A., Camm A.J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices // Ann. Med. - 2007. - Vol. 39. - P. 371391.
200.Bousser M.G., Bouthier J., Buller H.R. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial // Lancet. - 2008. - Vol. 371. - P. 315-321.
201.Attermann J. Inaccuracy of international normalized ratio (INR) measurements and suggestions for improved WHO guidelines for calibration of reference preparations: a statistical study // J. Thromb. Haemost. - 2003. - Vol. 1. - P. 537-544.
202.Hylek E.M., Skates S.J., Sheehan M.A. et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation // N. Engl. J. Med. - 1996. - Vol. 335. - P. 540-546.
203.Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin // Ann. Intern. Med. - 1994. - Vol. 120. - P. 897-902.
204.204. Odén A., Fahlén M. Oral anticoagulation and risk of death: medical record linkage study // Br. Med. J. - 2002. - Vol. 325. - P. 1073-1075.
205.205. Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? // JAMA. - 2003. - Vol. 290. - P. 2685-2692.
206.Hylek E.M., Evans-Molina C., Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation // Circulation. - 2007. - Vol. 115. - P. 26892696.
207.Reynolds M.W., Fahrbach K., Hauch O. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis // Chest. - 2004. - Vol. 126. - P. 1938-1945.
208.Bungard T.J., Ghali W.A., Teo K.K. et al. Why do patients with atrial fibrillation not receive warfarin? // Arch. Intern. Med. - 2000. - Vol. 160. - P. 41-46.
209.Lip G.Y., Kamath S., Jafri M. et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project // Stroke. - 2002. - Vol. 33. - P. 238-242.
210.Limdi N.A., Veenstra D.L. Warfarin pharmacogenetics. Pharma-cotherapy. - 2008. - Vol. 28. - P. 1084-1097.
211.Fitzmaurice D.A., Machin S.J., British Society of Haematology Task Force for Haemostasis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation // BMJ. - 2001. - Vol. 323. - P. 985-989.
212.Kalra L., Lip G.Y. Guideline Development Group for the NICE clinical guideline for the management of atrial fibrillation. Antithrom-botic treatment in atrial fibrillation // Heart. - 2007. - Vol. 93. - P. 39-44.
213.Sawicki P.T. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation // JAMA. - 1999. - Vol. 281. - P. 145-150.
214.Petersen P., Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation // Stroke. - 1986. - Vol. 17. - P. 622-626.
215.Inoue H., Atarashi H., for the Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation // Am. J. Cardiol. - 2000. - Vol. 86. - P. 852985.
216.Douketis J.D., Berger P.B., Dunn A.S. et al. - American College of Chest Physicians. The perioperative management of antithrombotic therapy: american College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition) // Chest. - 2008. - Vol. 133. (Suppl. 6). - P. 299S-339S.
217.Ruiz-Nodar J.M., Marín F., Hurtado J.A. et al. Anticoagulant and antiplatelet therapy use in
426. patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis // J. Am. Coll. Cardiol. - 2008. -
Vol. 51. - P. 818-825.
218.Lip G.Y., Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline // Chest. - 2006. - Vol. 130. - P. 1823-1827.
219.Rubboli A., Halperin J.L., Juhani Airaksinen K.E. et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation // Ann Med. - 2008. - Vol. 40. - P. 428-436.
220.Biblo L.A., Yuan Z., Quan K.J. et al. Risk of stroke in patients with atrial flutter // Am. J. Cardiol. - 2001. - Vol. 87. - P. 346-349, A9.
221.Bates S.M., Greer I.A., Pabinger I. et al. - American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. -
2008. - Vol. 133. (Suppl. 6). - P. 844S-886S.
222.American College of Cardiology/American Heart Association Task Force on Practice Guidelines. - Society of Cardiovascular Anesthe-siologists. - Society for Cardiovascular Angiography and Interventions. - Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006. guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998. Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons // Circulation. - 2007. - Vol. 115. - e409.
223.Berger M., Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis // Am. J. Cardiol. - 1998. - Vol. 82. - P. 1545-1546.
224.Gallagher M.M., Hennessy B.J., Edvardsson N. et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion // J. Am. Coll. Cardiol. - 2002. - Vol. 40. - P. 926-933.
225.Asher C.R., Klein A.L. Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation: aCUTE trial update // Card. Electrophysiol. Rev. - 2003. - Vol. 7. - P. 387-391.
226.Roijer A., Eskilsson J., Olsson B. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion // Eur. Heart J. - 2000. -
Vol. 21. - P. 837-847.
227.Stellbrink C., Nixdorff U., Hofmann T. et al. on behalf of the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin comparea with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial // Circulation. - 2004. - Vol. 109. - P. 997-1003.
228.Ezekowitz M.D., James K.E., Nazarian S.M. et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators // Circulation. - 1995. - Vol. 92. - P. 2178-2182.
229.Feinberg W.M., Seeger J.F., Carmody R.F. et al. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation // Arch. Intern. Med. - 1990. - Vol. 150. - P. 23402344.
230.Cullinane M., Wainwright R., Brown A. et al. Asymptomatic embolization in subjects with atrial fibrillation not taking anticoagulants:
a prospective study // Stroke. - 1998. - Vol. 29. - P. 1810-1815.
231.Johnson W.D., Ganjoo A.K., Stone C.D. et al. The left atrial appendage: our most lethal human attachment! Surgical implications // Eur. J. Cardiothorac Surg. - 2000. - Vol. 17. - P. 718-722.
232.Bayard Y.L., Ostermayer S.H., Sievert H. Alternatives to warfarin in atrial fibrillation: drugs and devices // Heart. - 2008. - Vol. 94. - P. 1113-1116.
233.Savelieva I., Camm J. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? // Am. Heart J. - 2007. - Vol. 154. - P. 403-406.
234.Camm A.J. Safety considerations in the pharmacological management of atrial fibrillation // Int. J. Cardiol. - 2008. - Vol. 127. - P. 299-306.
235.Dries D.L., Exner D.V., Gersh B.J. et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies Of Left Ventricular Dysfunction // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 695-703.
236.Pedersen O.D., Bagger H., Keller N. et al. for the Danish Investigation of Arrhythmia and Mortality ON Dofetilide Study Group. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy // Circulation. - 2001. - Vol. 104. - P. 292-296.
237.Wyse D.G., Waldo A.L., DiMarco J.P. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation //
N. Engl. J. Med. - 2002. - Vol. 347. - P. 1825-1833.
238.Van Gelder I.C., Hagens V.E., Bosker H.A. et al. for the Rate Control versus Electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation // N. Engl. J. Med. - 2002. -
Vol. 347. - P. 1834-1840.
239.Roy D., Talajic M., Nattel S. et al. for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure // N. Engl. J. Med. - 2008. -
Vol. 358. - P. 2667-2677.
240.Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation - pharmacological intervention in atrial fibrillation (PIAF): a randomised trial // Lancet. - 2002. - Vol. 356. - P. 1789-1794.
241.Carlsson J., Miketic S., Windeler J. et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. The Strategies of Treatment of Atrial Fibrillation Study // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1690-1696.
242.Opolski G., Torbicki A., Kosior D.A. et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How To Treat Chronic Atrial Fibrillation Study // Chest. - 2004. - Vol. 126. - P. 476-486.
243.De Denus S., Sanoski C.A., Carlsson J. et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis // Arch. Intern. Med. - 2005. - Vol. 165. - P. 258-262.
244.Corley S.D., Epstein A.E., DiMarco J.P. et al. - AFFIRM Inves-tigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study // Circulation. - 2004. - Vol. 109. -
P. 1509-1513.
245.Danias P.G., Caulfield T.A., Weigner M.J. et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 588-592.
246.Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence // Prog. Cardiovasc. Dis. - 2001. - Vol. 44. - P. 121-152.
247.Costeas C., Kassotis J., Blitzer M. et al. Rhythm management in atrial fibrillation - with a primary emphasis on pharmacological therapy: Part 2 // Pacing Clin. Electrophysiol. - 1998. - Vol. 21. - P. 742752.
248.Camm A.J., Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat // BMJ. - 2007. - Vol. 334. - P. 637.
249.Alboni P., Botto G.L., Baldi N. et al. Outpatient treatment of recent-onset atrial fibrillation with the ‘pill- in-the-pocket’ approach //
N. Engl. J. Med. - 2004. - Vol. 351. - P. 2384-2391.
250.Deneer V.H., Borgh M.B., Kingma J.H. et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation // Pharm. World Sci. - 2004. - Vol. 26. - P. 66-78.
251.Fresco C., Proclemer A., on behalf of the PAFIT-2. Investigators. Management of recent onset atrial fibrillation // Eur. Heart J. - 1996. - Vol. 17(Suppl. C): C41-47.
252.Bianconi L., Mennuni M., and PAFIT-3. Investigators. Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation // Am. J. Cardiol. - 1998. - Vol. 82. -
P. 584-588.
253.Boriani G., Biffi M., Capucci A. et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial // Ann. Intern. Med. - 1997. - Vol. 126. - P. 621-625.
254.Reimold S.C., Maisel W.H., Antman E.M. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis // Am. J. Cardiol. - 1998. - Vol. 82. - P. 66N-71N.
255.Capucci A., Boriani G., Botto G.L. et al. Conversion of recent-onset atrial fibrillation to sinus rhythm by a single oral loading dose of propafenone or flecainide // Am. J. Cardiol. - 1994. - Vol. 74. - P. 503-505.
256.Azpitarte J., Alvarez M., Baun O. et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation: results of a randomized double-blind, controlled study // Eur. Heart J. - 1997. - Vol. 18. - P. 1649-1654.
257.Alp N.J., Bell J.A., Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation // Heart. - 2000. - Vol. 84. - P. 37-40.
258.Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation // J. Am. Coll. Cardiol. - 2001. - Vol. 37. - P. 542-547.
259.Khan I.A. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation // Int. J. Cardiol. - 2003. -
Vol. 87. - P. 121-128.
260.Crijns H.J.G.H., van Gelder IC, Kingma J.H. et al. Atrial flutter can be terminated by a class III antiarrhythmic drug, but not by a class IC drug // Eur. Heart J. - 1995. - Vol. 15. - P. 1403-1408.
261.Vos M.A., Golitsyn S.R., Stangl K. et al. - for the Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over d,l-sotalol in converting atrial flutter and atrial fibrillation // Heart. - 1998. - Vol. 79. - P. 568-575.
262.Stambler B.S., Wood M.A., Ellenbogen K.A. et al. - and the Ibutilide Repeat Dose Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation // Circulation. - 1996. - Vol. 94. - P. 1613-1621.
263.Ellenbogen K.A., Stambler B.S., Woof M.A. et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study // J. Am. Coll. Cardiol. - 1996. - Vol. 28. -
P. 130-136.
264.Glatter K., Yang Y., Cjatterjee K. et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy // Circulation. - 2001. - Vol. 103. - P. 253-257.
265.Volgman A.S., Carberry P.A., Stambler B. et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 1414-1419.
266.Singh S, Zoble RG, Yellen L, et al. - for the Dofetilide Atrial Fibrillation Investigators. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study // Circulation. - 2000. - Vol. 102. - P. 2385-2390.
267.Greenbaum RA. European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide (EMERALD) // Circulation. - 1999. - Vol. 99. - P. 2486-2491. (Abstract).
268.Sung RJ, Tan HL, Karagounis L, et al. - for the Sotalol Multicenter Study Group. Intravenous sotalol for termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study // Am. Heart J. - 1995. - Vol. 129. - P. 739-748.
269.Halinen M.O., Huttunen M., Paakkinen S. et al. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial) // Am. J. Cardiol. - 1995. - Vol. 76. - P. 495-498.
270.Chevalier P., Durand-Dubief A., Burri H. et al. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis // J. Am. Coll. Cardiol. - 2003. - Vol. 41. -
P. 255-262.
271.Vardas P.E., Kochiadakis G.E., Igoumenidis N.E. et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study // Chest. - 2000. - Vol. 117. - P. 1538-1545.
272.Deedwania P.C., Singh B.N., Ellenbogen K. et al. - for the Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT) // Circulation. - 1998. - Vol. 98. - P. 2574-2579.
273.Galperín J., Elizari M.V., Chiale P.A. et al. - GEFCA Investigators-GEMA Group. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial //
J. Cardiovasc. Pharmacol Ther. - 2001. - Vol. 6. - P. 341-350.
274.Hohnloser S.H., Klingenheben T., Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia // Ann. Intern. Med. - 1994. - Vol. 121. - P. 529535.
275.Mattioli A.V., Lucchi G.R., Vivoli D. et al. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm // Clin. Cardiol. - 1998. - Vol. 21. - P. 763-766.
276.Madrid A.H., Moro C., Marin-Huerta E. et al. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation // Eur. Heart J. - 1993. - Vol. 14. - P. 1127-1131.
277.Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E. et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation // Am. J. Cardiol. - 2007. - Vol. 99. - P. 1721-1725.
278.Hohnloser S.H., Van de L.A., Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine // J. Am. Coll. Cardiol. -
1995. - Vol. 26. - P. 852-858.
279.Kerin N.Z., Faitel K., Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation // Arch. Intern. Med. - 1996. - Vol. 156. - P. 49-53.
280.Camm J., Ward D., Spurrell R.A. The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias // Br. J. Clin. Pharmacol. - 1979. - Vol. 8. - P. 441-449.
281.Camm A.J., Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant // J. Interv. Card. Electrophysiol. - 2008. - Vol. 23. - P. 7-14.
282.Roy D., Pratt C.M., Torp-Pedersen C. et al. - for the Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebocontrolled trial // Circulation. - 2008. - Vol. 117. - P. 1518-1525.
283.283. Roy D., Pratt C., Juul-Møller S. et al. - on behalf of the ACT III Investigators. Efficacy and tolerance of RSD1235. in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial // J. Am. Coll. Cardiol. - 2006. -
Vol. 47. (Suppl. A). - P. 10A (Abstract).
284.Roy D., Rowe B.H., Stiell I.G. et al. - CRAFT Investigators.
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2355-2361.
285.Onalan O., Crystal E., Daoulah A. et al. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation // Am. J. Cardiol. - 2007. - Vol. 99. - P. 1726-1732.
286.Falk R.H., Knowlton A.A., Bernard S.A. et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm // Ann. Intern. Med. - 1987. - Vol. 106. - P. 503-506.
287.The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Results of a randomized, placebocontrolled multicentre trial in 239. patients // Eur. Heart J. - 1997. - Vol. 18. - P. 649-654.
288.Tieleman R.G., Blaauw Y., Van Gelder I.C. et al. Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria // Circulation. - 1999. - Vol. 100. - P. 1836-1842.
289.Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A. et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials // Arch. Intern. Med. - 2006. - Vol. 166. - P. 719-728.
290.Kühlkamp V., Schirdewan A., Stangl K. et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study // J. Am. Coll. Cardiol. - 2000. - Vol. 36. - P. 139-146.
291.Plewan A., Lehmann G., Ndrepepa G. et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation: sotalol vs bisoprolol // Eur. Heart J. - 2001. - Vol. 22. - P. 1504-1510.
292.Katritsis D.G., Panagiotakos D.B., Karvouni E. et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation // Am. J. Cardiol. - 2003. - Vol. 92. - P. 1116-1119.
293.Nasr I.A., Bouzamondo A., Hulot J.S. et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis // Eur. Heart J. - 2007. - Vol. 28. - P. 457-462.
294.Geffner D.L., Hershman J.M. Beta-adrenergic blockade for the treatment of hyperthyroidism // Am. J. Med. - 1992. - Vol. 93. - P. 61-68.
295.Coumel P. Autonomic influences in atrial tachyarrhythmias // J. Cardiovasc. Electrophysiol. - 1996. - Vol. 7. - P. 999-1007.
296.Chimienti M., Cullen M.T., Jr., Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide And Propafenone Italian Study Investigators // Am. J. Cardiol. - 1996. -
Vol. 77. - P. 60A-75A.
297.Stroobandt R., Stiels B., Hoebrechts R., on behalf of the Propafenone Atrial Fibrillation Trial Investigators. Propafenone for conversion and prophylaxis of atrial fibrillation // Am. J. Cardiol. - 1997. - Vol. 79. -
P. 418-423.
298.UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation // Circula-tion. - 1995. - Vol. 92. - P. 2550-2557.
299.Pietersen A.H., Hellemann H., for the Danish-Norwegian Flecainide Multicenter Atrial Fibrillation Study Group. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter // Am. J. Cardiol. - 1991. - Vol. 67. - P. 713-717.
300.Naccarelli G.V., Dorian P., Hohnloser S. et al., for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter // Am. J. Cardiol. - 1996. - Vol. 77. - P. 53A-59A.
301.Pritchett E.L., Page R.L., Carlson M. et al. - Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation // Am. J. Cardiol. - 2003. - Vol. 92. - P. 941-946.
302.Meinertz T., Lip G.Y.H., Lombardi F. et al. - ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study) // Am. J. Cardiol. - 2002. - Vol. 90. - P. 13001306.
303.Okishige K., Fukunami M., Kumagai K. et al. Pilsicainide Suppression Trial for Persistent Atrial Fibrillation II Investigators. Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II // Circ. J. - 2006. - Vol. 70. - P. 657-661.
304.Komatsu T., Sato Y., Tachibana H, et al. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy // Circ. J. - 2006. - Vol. 70. - P. 667-672.
305.Coplen S.E., Antman E.M., Berlin J.A. et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials // Circulation. - 1990. - Vol. 82. - P. 1106-1116.
306.Karlson B.W., Torstensson I., Abjörn C. et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study // Eur. Heart J. -
1988. - Vol. 9. - P. 284-290.
307.Crijns H.J., Gosselink A.T., Lie K.I. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group // Cardiovasc. Drugs Ther. - 1996. - Vol. 10. -
P. 145-152.
308.De Paola A.A.V., Veloso H.H., for the SOCESP Investigators. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation // Am. J. Cardiol. - 1999. - Vol. 84. - P. 1033-1037.
309.Benditt D.G., Williams J.H., Jin J. et al. - for the d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter // Am. J. Cardiol. - 1999. - Vol. 84. - P. 270-277.